Bullish indicating open at $55-$60, IPO prices at $37
On Wednesday, JMP Securities maintained a positive stance on Inovio Pharmaceuticals (NASDAQ:INO), as analyst Roy Buchanan reiterated a Market Outperform rating and a $12.00 price target for the company’s stock. According to InvestingPro data, analyst targets for the stock range from $2.00 to $15.00, with the stock currently trading at $1.92. Buchanan highlighted that Inovio’s stability testing for its device array is currently in progress. He also pointed out that the company’s financial reserves are projected to be adequate beyond the acceptance of its Biologics License Application (BLA).
Inovio Pharmaceuticals recently disclosed its first-quarter results for 2025, which slightly surpassed both JMP’s and the consensus estimates, primarily due to lower-than-expected expenses. The company reported having $68 million in cash at the end of the quarter and confirmed that its financial runway is expected to extend into the first quarter of 2026. InvestingPro analysis shows the company maintains a healthy current ratio of 2.63, with more cash than debt on its balance sheet, though it’s currently burning through cash rapidly. Get access to 10+ additional ProTips and comprehensive financial metrics with InvestingPro.
The company has also reaffirmed its commitment to the submission schedule for its BLA for INO-3107, a treatment for recurrent respiratory papillomatosis (RRP). The submission is planned to be completed by the end of the year. Buchanan noted that INO-3107 is anticipated to receive priority review owing to its Breakthrough Therapy designation.
Even with the transition to a new FDA administration, Buchanan mentioned that Inovio’s communications with the regulatory body have remained consistent with previous interactions. This ongoing dialogue suggests a continuity in the company’s approach to seeking approval for its treatment. With a market capitalization of $70.41 million and current trading levels suggesting potential undervaluation according to InvestingPro’s Fair Value model, investors seeking deeper insights can access the comprehensive Pro Research Report, available exclusively to subscribers.
In other recent news, Inovio Pharmaceuticals Inc . reported a narrowed net loss of $19.7 million for the first quarter of 2025, a significant improvement from the $30.5 million loss in the same period last year. This was largely due to a 20% reduction in operating expenses. The company maintains a cash position of $68.4 million and estimates a net cash burn of approximately $22 million for the second quarter of 2025. Inovio plans to begin the rolling submission of its Biologics License Application for its lead candidate, INO-3107, in mid-2025, aiming for completion in the second half of the year. The company is also exploring potential partnerships outside the United States to expand its market reach. Analyst discussions during the earnings call highlighted the strategic importance of these developments for Inovio’s future. The company’s efforts to engage with the medical community through conferences and publications were also noted as part of their ongoing outreach strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.